



## Kura Oncology to Participate in Two Upcoming Investor Conferences

March 6, 2019

SAN DIEGO, March 06, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to present at two upcoming investor conferences:

- Cowen and Company Health Care Conference in Boston on March 12, 2019 at 9:20 a.m. ET / 6:20 a.m. PT; and
- Oppenheimer Healthcare Conference in New York on March 19, 2019 at 2:10 p.m. ET / 11:10 a.m. PT.

A live audio webcast and replay of each presentation will be available in the Investors section of Kura Oncology's website at [www.kuraoncology.com](http://www.kuraoncology.com).

### About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company's pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura's lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, for which the Company has initiated a registration-directed trial of tipifarnib in recurrent or metastatic patients with HRAS mutant HNSCC. In addition, tipifarnib is being evaluated in multiple other Phase 2 clinical trials in solid tumor and hematologic indications. Kura's pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 dose-escalation trial, and KO-539, a menin-MLL inhibitor, which is anticipated to enter into a Phase 1 clinical trial in the second quarter of 2019. For additional information about Kura Oncology, please visit the Company's website at [www.kuraoncology.com](http://www.kuraoncology.com).

### Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Kura Oncology's current expectations and involve assumptions that may never materialize, or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Kura Oncology's business and finances in general, and the other risks described in Kura Oncology's periodic and other filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Kura Oncology undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

### Contacts

Company:  
Pete De Spain  
Vice President, Investor Relations &  
Corporate Communications  
(858) 500-8803  
[pete@kuraoncology.com](mailto:pete@kuraoncology.com)

Investors:  
Robert H. Uhl  
Managing Director  
Westwicke Partners, LLC  
(858) 356-5932  
[robert.uhl@westwicke.com](mailto:robert.uhl@westwicke.com)

Media:  
Jason Spark  
Managing Director  
Canale Communications  
(619) 849-6005  
[jason@canalecomm.com](mailto:jason@canalecomm.com)



Source: Kura Oncology, Inc.